Regulators across financial services and healthcare are accelerating a push toward unified AI data provenance standards. Parallel rule-making in the United States and European Union is forcing institutions in both sectors to establish auditable, end-to-end records of how AI models are trained, validated, and deployed. The convergence reflects a growing consensus among standards bodies, prudential supervisors, and health regulators that fragmented lineage practices create systemic governance gaps-and legal exposure-that neither industry can afford.
Background
For years, financial institutions and health systems have operated under separate AI oversight regimes: banks governed by model risk management guidance SR 11-7 from the Federal Reserve, FDIC, and OCC, and hospitals subject to FDA device regulation, HIPAA, and emerging accreditation guidance from bodies such as the Joint Commission. Both regimes now converge around the same core demands: documented data lineage, traceable model versioning, access controls, and auditable decision logs.
The pressure intensified following a series of regulatory actions in 2024 and 2025. The EU AI Act entered into force on August 1, 2024, with obligations for general-purpose AI models applying from August 2, 2025, and full requirements for high-risk systems-including most healthcare AI and bank credit models-taking effect August 2, 2026. High-risk AI systems under the Act face mandatory data governance controls, transparency obligations, and post-market monitoring requirements. In the United States, the U.S. Government Accountability Office published report GAO-25-107197 on May 19, 2025, examining AI use and oversight across the financial services sector. The report found that federal financial regulators including the FDIC, Federal Reserve, and OCC rely on existing model risk management and third-party risk guidance to oversee AI, rather than developing new AI-specific regulations.
Healthcare regulators have moved in parallel. In 2025, the FDA issued draft guidance for AI-enabled devices focused on documentation, transparency, bias prevention, and post-market monitoring, adopting a "total product lifecycle" approach that recognizes algorithms will change and require continuous oversight. The Joint Commission and the Coalition for Health AI (CHAI) also published governance guidance, which, while currently non-binding, establishes seven foundational areas for AI adoption including oversight mechanisms, documented decision-making processes, and regulatory compliance.
Details
Despite the regulatory momentum, readiness gaps remain severe-especially in healthcare. According to Black Book Research, only 22% of hospitals report high confidence that they could deliver a complete, auditable AI explanation to regulators or payers within 30 days, while 44% report low confidence in their audit readiness. Data provenance is a particular vulnerability: over a third of hospitals (37%) report incomplete tracking of data inputs and model versions. Doug Brown, founder of Black Book Research, stated that "underinvestment is the quiet risk in hospital AI programs... Hospitals need audit trails, not just pilots, to prepare for 2026 scrutiny."
The challenge is structurally similar in banking, where institutions must demonstrate granular, attribute-level lineage to satisfy supervisory expectations. Under the European Central Bank's interpretation of BCBS 239, institutions are required to maintain "complete and up-to-date lineage at the data attribute level." The GAO report highlighted that the NCUA's model risk management guidance is limited in scope and does not provide sufficient detail on how credit unions should manage model risks, including AI models, and was last updated in 2016.
Standards bodies are working to bridge the two sectors. In March 2025, NIST updated its AI Risk Management Framework to emphasize model provenance, data integrity, and third-party model assessment. In December 2025, NIST released a preliminary draft Cybersecurity Framework Profile for Artificial Intelligence, developed with input from over 6,500 individuals, which maps AI-specific risks to the NIST CSF 2.0. For banks specifically, the draft states that institutions must verify the integrity of third-party AI models to prevent manipulation of credit scoring or fraud detection systems, per data provenance guidelines in the draft. The EU's European Health Data Space regulation, published in March 2025 and now in force, aims to standardize primary access and enable secure secondary use of health data across the EU, with key application milestones extending toward 2029.
Third-party vendor risk is an acute pressure point in both sectors. The GAO found that credit unions may find it difficult to evaluate the data sources used to train AI models, especially if the sources are opaque or unavailable. In financial services, practitioners note that regulators and supervisors expect firms to show not just who touched data, but what transformations occurred, why decisions used specific fields, and how controls were applied-particularly under BCBS 239 guidance. For multinational firms, diverging approaches between the EU's binding Act and the U.S. activity-based supervisory model add compliance complexity: the EU's laws will apply to non-EU providers, effectively exporting its regulatory standards, while the U.S. is likely to continue a more fragmented approach.
Outlook
With the EU AI Act's high-risk obligations taking effect in August 2026 and U.S. agencies signaling further refinement of model risk and third-party oversight guidance, institutions in both sectors face a compressed timeline. GAO recommended that Congress grant NCUA authority to examine technology service providers of credit unions, and that NCUA update its model risk management guidance to encompass a broader variety of models. In healthcare, Black Book Research recommends that hospitals shift at least two to three percentage points of their 2026 budget toward AI governance infrastructure, prioritizing model registries, lineage tracking, monitoring, and override logs. Organizations that delay building provenance architecture risk regulatory censure and the operational inability to explain AI-driven clinical and credit decisions on demand-a liability neither banks nor hospital systems can sustain.
